Organon & Co. (OGN) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $13.42 — A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away).
Organon & Co. is a global healthcare company with over 70 products across women's health (NEXPLANON, NuvaRing), biosimilars (BRUKINSA, Hadlima, Renflexis), and established brands (Zetia, Singulair, Nasonex), generating $6.2 billion in 2025 revenues. Approximately 74% of revenues... Read more
Sell if holding. Analyst target reached at $13.42 — A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away). Chart setup: RSI 59 mid-range, Bollinger mid-band. Score 5.7/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Organon & Co.
Latest news
- Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy — benzinga May 1, 2026 neutral
- Organon Q1 Adj. EPS $0.71 Misses $0.83 Estimate, Sales $1.460B Miss $1.484B Estimate — benzinga Apr 30, 2026 negative
- Organon Stock's Momentum Score Jumps As $11.75 Billion Sun Pharma Takeover Deal Sparks Global Pharma Consolidation Push — benzinga Apr 30, 2026 positive
- BNP Paribas Downgrades Organon to Neutral, Raises Price Target to $14 — benzinga Apr 29, 2026 negative
- Organon And Henlius Secure European Commission Approval For POHERDY, The First Pertuzumab Biosimilar Authorized In Europ — benzinga Apr 29, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $13.42 — A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away). Chart setup: RSI 59 mid-range, Bollinger mid-band. Prior stop was $13.26. Score 5.7/10, moderate confidence.
Take-profit target: $13.20 (-1.6% upside). Prior stop was $13.26. Stop-loss: $13.26.
Analyst target reached - limited upside remaining; Near 52-week high (0.4% away); Leverage penalty (D/E 9.5): -1.5.
Organon & Co. trades at a P/E of 14.4 (forward 3.7). TrendMatrix value score: 8.0/10. Verdict: Sell.
13 analysts cover OGN with a consensus score of 2.5/5. Average price target: $11.
What does Organon & Co. do?Organon & Co. is a global healthcare company with over 70 products across women's health (NEXPLANON, NuvaRing),...
Organon & Co. is a global healthcare company with over 70 products across women's health (NEXPLANON, NuvaRing), biosimilars (BRUKINSA, Hadlima, Renflexis), and established brands (Zetia, Singulair, Nasonex), generating $6.2 billion in 2025 revenues. Approximately 74% of revenues were generated outside the United States across 140+ countries.